Glucose Tolerance Test + Continuous Glucose Monitoring for Postpartum High Blood Sugar
Trial Summary
Will I have to stop taking my current medications?
The trial information does not specify whether you need to stop taking your current medications. It might be best to discuss this with the trial coordinators or your doctor.
What data supports the effectiveness of the treatment 2-hour 75-g oral glucose tolerance test and Dexcom G6 Pro continuous glucose monitor for postpartum high blood sugar?
The 2-hour 75-g oral glucose tolerance test is effective in identifying women with glucose intolerance after pregnancy, as it is better at detecting issues than just measuring fasting blood sugar. Continuous glucose monitoring, like the Dexcom G6 Pro, helps track blood sugar patterns closely, which can be useful in managing diabetes during pregnancy.12345
Is the 2-hour 75-g oral glucose tolerance test safe for use in humans?
How does the treatment using a 2-hour 75-g oral glucose tolerance test and Dexcom G6 Pro continuous glucose monitor differ from other treatments for postpartum high blood sugar?
This treatment is unique because it combines a 2-hour 75-g oral glucose tolerance test, which measures how well your body processes sugar, with the Dexcom G6 Pro continuous glucose monitor, which tracks blood sugar levels in real-time. This combination allows for a more comprehensive assessment of glucose tolerance and continuous monitoring, which is not typically offered in standard postpartum glucose testing.1571011
What is the purpose of this trial?
This trial uses a device to track blood sugar levels in women who had diabetes during pregnancy. These women are at high risk for developing type 2 diabetes later. The study aims to understand their blood sugar patterns after childbirth and improve screening methods for diabetes.
Eligibility Criteria
This trial is for women who had gestational diabetes during a single pregnancy with no fetal anomalies, diagnosed before 20 weeks or at/after 24 weeks and required medication. It's not for those with skin conditions affecting glucose monitor use, history of prediabetes, PCOS, or pregestational type 2 diabetes.Inclusion Criteria
Exclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Initial Assessment
Participants undergo an oral glucose tolerance test and start wearing a continuous glucose monitor for 10 days
Follow-up Assessment 1
Participants continue to wear a continuous glucose monitor for 10 days and undergo assessments of insulin secretion and sensitivity
Follow-up Assessment 2
Participants wear a continuous glucose monitor for 10 days and undergo final assessments of insulin secretion and sensitivity
Follow-up
Participants are monitored for safety and effectiveness after treatment
Treatment Details
Interventions
- 2-hour 75-g oral glucose tolerance test
- Dexcom G6 Pro continuous glucose monitor
Find a Clinic Near You
Who Is Running the Clinical Trial?
University of Alabama at Birmingham
Lead Sponsor
University of North Carolina, Chapel Hill
Collaborator